Combination therapy with valproic acid in cancer: Initial clinical approach

Drugs of the Future

Volumn 32, Issue 1, 2007, Pages 45-50

  McIntyre, J ^a   Moral, Ma Àngels ^a   Bozzo, J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMINOPHYLLINE; AZACITIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HISTONE DEACETYLASE; HYDRALAZINE; RETINOIC ACID; RNA POLYMERASE; TEMOZOLOMIDE; TRANSCRIPTION FACTOR; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANTICONVULSANT ACTIVITY; BLOOD TOXICITY; BREAST CANCER; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSCIOUSNESS; CONTROLLED CLINICAL TRIAL; CONVULSION; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG RESEARCH; ENDOMETRIUM CANCER; ENZYME INHIBITION; EPILEPSY; GENE SILENCING; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; KAPOSI SARCOMA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOOD DISORDER; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NASOPHARYNX CARCINOMA; NEUROTOXICITY; NONHUMAN; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TRANSCRIPTION INITIATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

EID: 34247597896     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2007.032.01.1052960     Document Type: Review

References (38)

1. Gottlicher, M., Minucci, S., Zhu, P. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001, 20(24): 6969-78.
2. Gottlicher, M. Valproic acid: An old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 2004, 83(Suppl. 1): S91-2.
3. Gurvich, N., Tsygankova, O.M., Meinkoth, J.L., Klein, P.S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004, 64(3): 1079-86.
4. Sorbera, L.A. Epigenetic targets as an approach to cancer therapy and prevention. Drugs Fut 2006, 31(4): 335-44.
5. Galm, O., Herman, J.G., Baylin, S.B. The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev 2006, 20(1): 1-13.
6. Mongan, N.P., Gudas, L.J. Valproic acid, in combination with all-trans retinole acid and 5-aza-2′-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Mol Cancer Ther 2005, 4(3): 477-86.
7. Takai, N., Desmond, J.C., Kumagai, T. et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 2004, 10(3): 1141-9.
8. Graziani, G., Tentori, L., Portarena, I., Vergati, M., Navarra, P. Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells. Endocrinology 2003, 144(7): 2822-8.
9. Bug, G., Gul, H., Schwarz, K. et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005, 65(7): 2537-41.
10. Qi, H., Ratnam, M. Synergistic induction of folate receptor beta by all-trans retinole acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: Mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Res 2006, 66(11): 5875-82.
11. Knuepfer, M.M., Hernaiz-Driever, P., Poppenborg, H., Wolff, J.E., Cinatl, J. Valproic acid inhibits proliferation and changes expression of CD44 and CD56 of malignant glioma cells in vitro. Anticancer Res 1998, 18(5A): 3585-90.
12. Catalano, M.G., Fortunati, N., Pugliese, M., Costantino, L., Poli, R., Bosco, O., Boccuzzi, G. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2005, 90(3): 1383-9.
13. +/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 2004, 89(2): 1006-9.
14. Xia, Q., Sung, J., Chowdhury, W. et al. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res 2006, 66(14): 7237-44.
15. Chavez-Blanco, A., Perez-Plasencia, C., Perez-Cardenas, E. et al. Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines. Cancer Cell Int 2006, 6: 2.
16. Chavez-Blanco, A., Segura-Pacheco, B., Perez-Cardenas, E. et al. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol Cancer 2005, 4(1): 22.
17. Atmaca, A., Maurer, A., Heinzel, T. et al. A dose-escalating phase I study with valproic acid (VPA) in patients (pts) with advanced cancer. J Clin Oncol 2004, 22(14, Suppl.): Abst 3169.
18. Garcia-Manero, G., Kantarjian, H., Sanchez-Gonzalez, B. et al. Results of a phase I/II study of the combination of 5-aza-2′-deoxycytidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome. 41st Annu Meet Am Soc Clin Oncol (ASCO) (May 13-17, Orlando) 2005, Abst 6544.
19. Garcia-Manero, G., Kantarjian, H., Sanchez-Gonzalez, B. et al. Final results of a phase I/II study of the combination of the hypomethylating agent 5-aza-2′-deoxycytidine (DAC) and the histone deacetylase inhibitor valproic acid (VPA) in patients with leukaemia. Blood [47th Annu Meet Am Soc Hematol (Dec 10-13, Atlanta) 2005] 2005, 106(11): Abst 408.
20. Raffoux, E., Chaibi, P., Dombret, H., Degos, L. Valproic acid and all-trans retinole acid for the treatment of elderly patients with acute myeloid leukaemia. Haematologica 2005, 90(7): 986-8.
21. Kuendgen, A., Strupp, C., Aivado, M. et al. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 2004, 104(5): 1266-9.
22. Kuendgen, A., Knipp, S., Fox, F. et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia. Ann Hematol 2005, 84(Suppl. 13): 61-6.
23. Kuendgen, A. et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukaemia. Cancer 2006, 106(1): 112-9.
24. Bug, G., Ritter, M., Wassmann, B. et al. Clinical trial of valproic acid and all-trans retinole acid in patients with poor-risk acute myeloid leukaemia. Cancer 2005, 104(12): 2717-25.
25. Pilatrino, C., Cilloni, D., Messa, E. et al. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid. Cancer 2005, 104(1): 101-9.
26. Differentiation induction in acute myelogenous leukemia (NCT00175812). ClinicalTrials.gov Web site 2006.
27. Decitabine and valproic acid in treating patients with refractory or relapsed acute myeloid leukemia or previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (NCT00079378). ClinicalTrials.gov Web site 2006.
28. Decitabine with or without valproic acid in treating patients with relapsed or refractory non-Hodgkin's lymphoma (NCT00109824). ClinicalTrials.gov Web site 2006.
29. Phase I/II 5-azacytidine plus VPA plus ATRA (NCT00326170). ClinicalTrials.gov Web site 2006.
30. Study on valproic acid, all-trans retinoic acid and their combination in induction and consolidation therapy as well as pegfilgrastim after consolidation therapy in younger patients with newly diagnosed acute myeloid leukemia (NCT00151242). ClinicalTrials.gov Web site 2006.
31. Study on valproic acid in combination with all-trans retinoic acid, standard induction- and consolidation therapy in older patients with newly diagnosed acute myeloid leukemia (NCT00151255). ClinicalTrials.gov Web site 2006.
32. Munster, P.N., Marchion, D.C., Bicaku, E. et al. Pharmacokinetic and pharmacodynamic analysis of the histone deacetylase inhibitor, valproic acid in combination with the topoisomerase II inhibitor, epirubicin in solid tumor malignancies. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst B164.
33. Phase I trial of valproic acid and epirubicin in solid tumor malignancies (NCT00246103). ClinicalTrials.gov Web site 2006.
34. Decitabine and valproic acid in treating patients with non-small cell lung cancer (NCT00084981). ClinicalTrials.gov Web site 2006.
35. Valproic acid in treating young patients with recurrent or refractory solid tumors or CNS tumors (NCT00107458). ClinicalTrials.gov Web site 2006.
36. Valproic acid, temozolomide, and radiation therapy in treating patients with glioblastoma multiforme (NCT00313664). ClinicalTrials.gov Web site 2006.
37. Valproic acid in the induction of EBV lytic cycle antigen expression in nasopharyngeal carcinoma (NCT00181220). ClinicalTrials.gov Web site 2006.
38. Valproic acid in treating patients with Kaposi's sarcoma (NCT00075777). ClinicalTrials.gov Web site 2006.